摘要
目的:探讨子痫前期血清对肾小球内皮细胞(HRGEC)通透性的影响以及caveolin-1表达在子痫前期血清影响HRGEC通透性过程中的作用。方法:采用原代培养的肾小球内皮细胞,实验分组:正常妊娠血清培养组(A组),子痫前期血清培养组(B组),子痫前期血清+caveolae蛋白的抑制剂甲基-β-环糊精(MBCD)处理组(C组)。免疫荧光及免疫印迹监测HRGEC caveolin-1蛋白表达;细胞接种transwell小室,Evens-blue检测HRGEC单层细胞对大分子蛋白通透性改变;Western blot法检测caveolin-1表达。结果:子痫前期血清明显促进单层HRGEC对大分子蛋白的通透性与caveolin-1表达(P<0.05),MBCD能拮抗子痫前期血清促单层HRGEC对大分子蛋白的通透性与caveolin-1表达的作用。结论:子痫前期患者血清通过增加caveolin-1蛋白表达促进HRGEC单层细胞对大分子蛋白的通透性,caveolin-1表达异常可能在子痫前期患者蛋白尿形成过程中起重要作用。
Objective: To explore the serum impacts on the permeability of human renal glomerular endothelial cells( HRGEC) in preeclampsia patients and the function of expressed caveolin-1 on the permeability of HRGEC. Method: To culture the primary HRGEC and observe the position of Caveolin-1 in HRGEC by immunofluorescence. Then culture HRGEC in a device called "transwell". Three groups were divided: Group A was treated with the serum of normal pregnant when the cells overgrew the whole upper chamber. Group B was treated with the preeclampsia patients serum. Group C was treated with the same preeclampsia serum as the second group and also one caveolae inhibitor- Methyl-beta- cyclodextrinthe( MBCD) in a suitable concentration. And then test the Evans-bule conjuncted BSA in the lower chamber to reflect the dynamic permeability of HRGEC. Western blot was used to detect the quantity of caveolin-1 expressed by HRGEC after the cells were stimulated by serums of each group for 24 hours. Result: the permeability of HRGEC was significantly enhanced when they were dealt with preeclampsia serum and the inhibitor could reverse them partly( P 〈0. 05). The expression of caveolin-1 was highly elevated( P 〈0. 05),it was reduced when treated with MBCD( P 〈0. 05). Conclusion: High expressed caveolin-1in preeclampsia patients can lead to hyperpermeability of HRGEC,which may play an important role in proteinuria formation in preeclampsia patients.
出处
《现代妇产科进展》
CSCD
北大核心
2016年第1期10-13,18,共5页
Progress in Obstetrics and Gynecology
基金
国家自然科学基金资助项目(No:81570444)
国家科技部"十二五"支撑计划项目(No:2014BAI05B05)
上海交通大学医学院健康管理研究基金(LY201501)